SALT LAKE CITY and TORONTO, May 28, 2015 (Marketwire/-) EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has announced today its collaboration with the University of Guelph, Department of Molecular and Cellular Biology. The collaboration involves evaluation of the antimicrobial activity of the company’s natural antibacterial products, Cleanezze™ and VClean™.
Cleanezze™ is a natural hand sanitizer that contains 3 different antibacterial compounds.
VClean™ is a natural, non-toxic and highly effective concentrate for the elimination of dangerous germs from surfaces including fruits, vegetables, kitchen tools etc.
Information on EastGate’s natural product line can be found at www.nano-essentials.com
The research team at the University of Guelph is led by Principal Investigator Dr. Cezar Khursigara. The study demonstrated that both Cleanezze™ and VClean™ possess enhanced activity against common foodborne pathogens such as E. coli, Salmonella and Listeria species. Furthermore, Cleanezze™ demonstrated a significant “barrier effect” and can prevent the foodborne pathogens from attaching to skin surfaces. The University of Guelph team is now extending these highly encouraging studies in order to quantify the antimicrobial properties of these natural products.
The study was partially funded by a grant from Canada’s Natural Sciences and Engineering Research Council. Future grant applications are being considered.
“We believe that our research collaboration with the University of Guelph plays a key role in validating the anti-bacterial effectiveness of both Cleanezze™ and VClean™” says Anna Gluskin, EastGate’s CEO. “With many outbreaks of pathogenic bacteria in the food industry, hospitals and other public institutions the demand for safe and effective antimicrobial products is growing; our unique delivery system allows our products to offer higher efficacy and extended antibacterial protection” continues Gluskin.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbour” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.